Functional Parameters of Nutrition

  • Max Dahele
  • Kenneth C. H. Fearon


Functional assessment is at the heart of understanding how a chronic disease and its therapy impact on patients. It puts into tangible terms what the patient is capable of and brings an understandable ‘human context’ to the patient burden. Functional status can be a prognostic indicator. It may also have a role in treatment selection for individual patients and be used to enter and stratify patients in clinical trials. It remains to be seen whether it will be possible and practical to use end-points such as function (and other related end-points such as ‘quality of life’) to direct individual patient management. Using cancer cachexia as a paradigm, this chapter sets out to discuss some of the broader issues in functional patient assessment. New approaches to assessing function and preliminary experience with an emerging technology are also presented.


Physical Activity Level Functional Assessment Total Energy Expenditure Cancer Cachexia Comprehensive Geriatric Assessment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Simons JP, Aaronson NK, Vansteenkiste JF et al (1996) Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advancedstage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol 14:1077–1084PubMedGoogle Scholar
  2. 2.
    Maloney FI, Barthel DW (1965) Functional evaluation: the Barthel Index. MD St Med J 14:61–65Google Scholar
  3. 3.
    Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186PubMedGoogle Scholar
  4. 4.
    Rueben DB, Laliberte L, Hiris J, Mor V (1990) A hierarchical exercise scale to measure function at the advanced activities of daily living (AADL) level. J Am Geriatr Soc 38:855–861Google Scholar
  5. 5.
    Trentini M, Semeraro S, Motta M (2001) Italian Study Group for Geriatric Assessment and Management. Effectiveness of geriatric evaluation and care. One-year results of a multicenter randomized clinical trial. Aging (Milan) 13:395–405Google Scholar
  6. 6.
    Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 199–205Google Scholar
  7. 7.
    Anonymous (1979) WHO Handbook for Reporting Results of Cancer Treatment. World Health Organisation, GenevaGoogle Scholar
  8. 8.
    Slevin ML, Plant H, Lynch D et al (1988) Who should measure quality of life, the doctor or the patient? Br J Cancer 57:109–112PubMedGoogle Scholar
  9. 9.
    Blagden SP, Charman SC, Sharpies LD et al (2003) Performance status score: do patients and their oncologists agree? Br J Cancer 89:1022–1027PubMedCrossRefGoogle Scholar
  10. 10.
    Zubrod GC, Schneiderman M, Frei E et al (1960) Appraisal of methods for study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphamide. J Chron Dis 11:7–33CrossRefGoogle Scholar
  11. 11.
    Schaafsma J, Osoba D (1994) The Karnofsky Performance Status Scale re examined: a cross-validation with the EORTC-C30. Qual Life Res 3:413–424PubMedCrossRefGoogle Scholar
  12. 12.
    Schag CC, Heinrich RL (1984) Karnofsky Performance Status revisited: reliability, validity and guidelines. J Clin Oncol 2:193–197Google Scholar
  13. 13.
    Jatoi A, Hillman S, Stella PJ et al (2003) Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. Support Care Cancer 11:460–464PubMedCrossRefGoogle Scholar
  14. 14.
    Osoba D (1999) What has been learned from measuring health-related quality of life in clinical oncology. EurJ Cancer 35:1565–1570CrossRefGoogle Scholar
  15. 15.
    Anonymous (1949) World Health Organisation. Constitution in Basic Documents. World Health Organisation, GenevaGoogle Scholar
  16. 16.
    McHorney CA, Ware JE, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–263PubMedCrossRefGoogle Scholar
  17. 17.
    Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRefGoogle Scholar
  18. 18.
    Cella DF, Tulsky DS, Gray G et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin One 11:570–579Google Scholar
  19. 19.
    Cohen SR, Leis A (2002) What determines the quality of life of terminally ill cancer patients from their own perspective? J Palliat Care 18:48–58PubMedGoogle Scholar
  20. 20.
    Greisinger AJ, Lorimor RJ, Aday LA et al (1997) Terminally ill cancer patients. Their most important concerns. Cancer Pract 5:147–154PubMedGoogle Scholar
  21. 21.
    Steinhauser KE, Christakis NA, Clipp EC et al (2000) Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 284:2476–2482PubMedCrossRefGoogle Scholar
  22. 22.
    Cella D, Chang CH, Lai JS, Webster K (2002) Advances in quality of life measurements in oncology patients. Semin Oncol 29(Suppl 8):60–68PubMedCrossRefGoogle Scholar
  23. 23.
    Waldron D, O’Boyle CA, Kearney M et al (1999) Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol 17:3603–3611PubMedGoogle Scholar
  24. 24.
    Gough IR, Furnival CM, Schilder L, Grove W (1983) Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 19:1161–1165PubMedCrossRefGoogle Scholar
  25. 25.
    Nordin K, Steel J, Hoffman K, Glimelius B (2001) Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients. Br J Cancer 85:1265–1272PubMedCrossRefGoogle Scholar
  26. 26.
    Ballatori E (2001) Unsolved problems in evaluating the quality of life of cancer patients. Ann Oncol 12(Suppl 3):S11–S13PubMedCrossRefGoogle Scholar
  27. 27.
    Holzner B, Kemmler G, Sperner-Unterweger B et al (2001) Quality of life measurement in oncology—a matter of the assessment instrument? Eur J Cancer 37:2349–2356PubMedCrossRefGoogle Scholar
  28. 28.
    Hakamies-Blomqvist L, Luoma ML, Sjostrom J et al (2001) Timing of quality of life (QoL) assessments as a source of error in oncological trials. J Adv Nurs 35:709–716PubMedCrossRefGoogle Scholar
  29. 29.
    Conroy T, Bleiberg H, Glimelius B (2003) Quality of life in patients with advanced colorectal cancer: what has been learnt? Eur J Cancer 39:287–294PubMedCrossRefGoogle Scholar
  30. 30.
    Wasson J, Keller A, Rubenstein L et al (1992) Benefits and obstacles of health status assessment in ambulatory settings. The clinician’s point of view. The Dartmouth Primary Care COOP Project. Med Care 30:MS42–MS49PubMedCrossRefGoogle Scholar
  31. 31.
    Raiten DJ, Talbot JM (eds) (1999) Proceedings of the workshop ‘Clinical Trials for the Treatment of Secondary Wasting and Cachexia: Selection of Appropriate Endpoints’, May 22–23, 1997, Bethesda. J Nutr l29:223S–317SGoogle Scholar
  32. 32.
    Jatoi A, Daly BD, Hughes VA et al (2001) Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure? Ann Thorac Surg 72:348–351PubMedCrossRefGoogle Scholar
  33. 33.
    MacDonald N, Easson AM, Mazurak VC et al (2003) Understanding and managing cancer cachexia. J Am Coll Surg 197:143–161PubMedCrossRefGoogle Scholar
  34. 34.
    Tisdale MJ (2001) Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci 6:D164–D174PubMedCrossRefGoogle Scholar
  35. 35.
    Fearon KC, Hansell DT, Preston T et al (1988) Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. Cancer Res 48:2590–2595PubMedGoogle Scholar
  36. 36.
    Todorov P, Cariuk P, McDevitt T et al (1996) Characterization of a cancer cachectic factor. Nature 379:739–742PubMedCrossRefGoogle Scholar
  37. 37.
    Scott HR, McMillan DC, Brown DJ et al (2003) A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer 40:295–299PubMedGoogle Scholar
  38. 38.
    Persson C, Glimelius B (2002) The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res 22:3661–3668PubMedGoogle Scholar
  39. 39.
    O’Gorman P, McMillan DC, McArdle CS (1998) Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer 32:76–80CrossRefGoogle Scholar
  40. 40.
    O’Gorman P, McMillan DC, McArdle CS (1999) Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutr Cancer 35:127–129CrossRefGoogle Scholar
  41. 41.
    O’Gorman P, McMillan DC, McArdle CS (2000) Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37:36–40CrossRefGoogle Scholar
  42. 42.
    Sarna L (1993) Fluctuations in physical function: adults with non-small cell lung cancer. J Adv Nurs 18:714–724PubMedCrossRefGoogle Scholar
  43. 43.
    Yadav RR, Fossella F, Palmer JL et al (2003) An objective evaluation of functional ability (OEF) in patients with advanced lung cancer. Proc Am Soc Clin Oncol 22:746 (abs)Google Scholar
  44. 44.
    Simmonds MJ (2002) Physical function in patients with cancer: psychometric characteristics and clinical usefulness of a physical performance test battery. J Pain Symptom Manage 24:404–414PubMedCrossRefGoogle Scholar
  45. 45.
    Bennett CL, Greenfield S, Aronow HU et al (1991) Patterns of care related to age of men with prostate cancer. Cancer 67:2633–2641PubMedCrossRefGoogle Scholar
  46. 46.
    Newschaffer CJ, Penberthy L, Desch CD et al (1996) The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 156:85–90PubMedCrossRefGoogle Scholar
  47. 47.
    Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404–1411PubMedCrossRefGoogle Scholar
  48. 48.
    Schambelan M, Mulligan K, Grunfeld C et al (1996) Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 125:873–882PubMedGoogle Scholar
  49. 49.
    Schutz Y,W einsier RL, Hunter GR (2001) Assessment of free-living physical activity in humans: an overview of currently available and proposed new measures. Obes Res 9:368–379PubMedCrossRefGoogle Scholar
  50. 50.
    Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25(3 Suppl 7):43–46PubMedGoogle Scholar
  51. 51.
    Gibney ER (2000) Energy expenditure in disease: time to revisit? Proc Nutr Soc 59:199–207PubMedGoogle Scholar
  52. 52.
    Ritz P, Coward WA (1995) Doubly labelled water measurement of total energy expenditure. Diabete Metab 21:241–251PubMedGoogle Scholar
  53. 53.
    Moses AW, Slater C, Preston T et al (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90:996–1002PubMedCrossRefGoogle Scholar
  54. 54.
    Ma J, Barbenel JC (1997) A new ambulatory monitoring instrument of posture and mobility related activities. Biomed Sci Instrum 33:88–93PubMedGoogle Scholar
  55. 55.
    Matsuoka S, Yonezawa Y, Maki H et al (2003) A microcomputer-based daily living activity recording system. Biomed Sci Instrum 39:220–223PubMedGoogle Scholar
  56. 56.
    Aminian K, Robert P, Buchser EE et al (1999) Physical activity monitoring based on accelerometry: validation and comparison with video observation. Med Biol Eng Comput 37:304–308PubMedCrossRefGoogle Scholar
  57. 57.
    Makikawa M, Kurata S, Kawato M et al (1998) Ambulatory physical activity monitoring system. Medinfo 9 (Pt 1):277–281PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Max Dahele
    • 1
  • Kenneth C. H. Fearon
    • 1
  1. 1.Department of Clinical and Surgical Sciences (Surgery)The University of EdinburghRoyal InfirmaryUK

Personalised recommendations